Our Approach
At GH Research, we focus on achieving the highest level of quality in our work, coupled with fresh thinking and an entrepreneurial spirit. Providing a truly meaningful therapy to patients who have been underserved by available options, often for many years, is a highly ambitious goal and one that requires bright, passionate people to see it through. We have assembled such a team – one that understands the challenges involved in transforming next-generation mental health therapies from concept to reality and that is committed to all stakeholders invested in our mission and to fostering a positive transformation within the healthcare industry.
Our History
GH Research was founded in 2018, and since then, two of our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates have entered clinical development; our lead product candidate, GH001, is currently being investigated in a randomized, double-blind, placebo-controlled Phase 2b trial in patients with TRD, and in two open-label Phase 2a proof-of-concept trials in patients with bipolar II disorder with a depressive episode (BDII) and patients with postpartum depression (PPD).
Our Timeline
2018
Foundation of GH Research and technical development work of drug product.
2019
Completed Phase 1 clinical trial of GH001 in healthy volunteers (GH001-HV-101) and initiated Phase 1/2 clinical trial of GH001 in patients with TRD (GH001-TRD-102)
2020
Secured Series A financing
2021
- Secured Series B financing
- Completed Phase 1 of our Phase 1/2 clinical trial of GH001 in patients with TRD (GH001-TRD-102)
- Listed on NASDAQ stock exchange as a public company following an upsized initial public offering
- Expanded product candidate portfolio with GH002 and GH003, our proprietary injectable and intranasal mebufotenin product candidates
- Completed Phase 2 of our Phase 1/2 clinical trial of GH001 in patients with TRD (GH001-TRD-102)
- Completed our Phase 1 clinical pharmacology trial of GH001 in healthy volunteers (GH001-HV-103)
2022
- Initiated Phase 2a proof-of-concept clinical trials of GH001 for the treatment of patients with BDII with a current depressive episode (GH001-BD-202)
- Initiated Phase 2a proof-of-concept clinical trial of GH001 for the treatment of patients with PPD (GH001-PPD-203)
- Initiated Phase 1 clinical pharmacology trial of GH002 in healthy volunteers (GH002-HV-105)
2023
- Initiated Phase 2b clinical trial of GH001 in patients with TRD (GH001-TRD-201)
- Completed our Phase 1 clinical pharmacology trial of GH002 in healthy volunteers (GH002-HV-105)